P-001 - Overexpression of HER-2/neu in Resectable Esophageal Squamous Cell Carcinoma

Date 04 July 2015
Event WorldGI 2015
Session Posters
Topics Oesophageal Cancer
Pathology/Molecular Biology
Presenter A. Taghizadeh
Citation Annals of Oncology (2015) 26 (suppl_4): 1-100. 10.1093/annonc/mdv233
Authors A. Taghizadeh, R. Bagheri, M.A. Aghdasi
  • MUMS, Mashhad/IR

Abstract

Introduction

Amplification and overexpression of HER-2 proto-oncogene occurs in many human cancers such as ovarian, breast and gastric cancers which is linked to poor prognosis of these tumors. Since, there is no appropriate marker for the prognosis and treatment of esophageal cancer, current study aimed to evaluate Her-2/neu expression and its relationship with clinicopathologic factors.

Methods

This cross-sectional study was carried out on 64 patients with primary esophageal Squamous Cell Carcinoma (ESCC) who were histologically diagnosed and exposed to surgery for curative treatment and staging in the Department of Thoracic Surgery, Qhaem University Hospital, Mashhad, Iran between 2009 and 2012. Immunohistochemistry (IHC) was used to assess expression of HER-2/neu receptor in formalin-fixed paraffin-embedded tissue blocks. Then, HER-2 gene amplification was evaluated by fluorescence in situ hybridisation (FISH) assay.

Results

The mean age of patients was 60.1 ± 1.28 years old (60.8 ± 1.7 in men and 59.5 ± 1.9 in women). Her2/neu overexpression was 51.5%, which was significantly associated with the tumor differentiation (p < 0.001). 17 patients (26.2%) had vascular invasion, 12 patients (18.8%) had neuronal invasion and 7 patients (10.9%) had invasion to margins. There was no relationship between vascular, Perineural and margins invasion with HER-2/neu overexpression. Nine of 12 patients with HER-2/neu overexpression had thoracic tumors and only three of them had an abdominal ESCC, however, there was no relationship between Her2/neu overexpression with site of involvement & stage of tumor.

Conclusion

Her2/neu overexpression in patients with primary ESCC is almost high and had a reverse relationship with tumor differentiation, which might suggest using of Her2/neu over expression as a useful target for immunotherapy of these cancers.